ZURA 250117 7.50P (ZURA250117P7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

ZURA250117P7500

Watchlist

0.00
0.000.00%

15min DelayClose Dec 27 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)
TipRanksDec 25 06:51 ET · Ratings
Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks
TipRanksDec 24 06:15 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target
BenzingaDec 24 06:13 ET
Zura Bio Begins Phase 2 Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
MT NewswiresDec 23 09:51 ET
Express News | Zura Bio Launches Global Phase 2 Tibusure Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
ReutersDec 23 06:44 ET
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
BusinesswireDec 23 06:30 ET

Comments

Jaguar8

Nov 14 15:32

NEWS

$Zura Bio (ZURA.US)$
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Methodman10

Oct 17 14:32

$Zura Bio (ZURA.US)$ big move ahead. daily chart looks great

Trytosaveabit

Jun 14 05:04

Update

$Zura Bio (ZURA.US)$ Zura Bio Ltd: Tibulizumab (Zb-106) Was Well Tolerated and Neutralized Il-17a and Baff in a Phase 1 Study in Patients With Sjogren's Syndrome! Presents data at EULAR 2024

Drosen21

Jun 12 08:09

Hedgies may be confused over at Cantor…

$Zura Bio (ZURA.US)$ One is overweight and another to buy 🤫

Jaguar8

Jun 3 06:31

NEWS

$Zura Bio (ZURA.US)$
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...